U.S. markets closed

iCAD, Inc. (ICAD)

NasdaqCM - NasdaqCM Precio en tiempo real. Divisa en USD.
Añadir a la lista de seguimiento
1.6100+0.0100 (+0.62%)
Al cierre: 04:00PM EDT
1.6100 0.00 (0.00%)
Fuera de horario: 04:00PM EDT

iCAD, Inc.

98 Spit Brook Road
Suite 100
Nashua, NH 03062
United States
603 882 5200
https://www.icadmed.com

Sector(es)Healthcare
IndustriaMedical Devices
Empleados a tiempo completo

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Ms. Dana R. BrownPresident, CEO & Executive ChairN/DN/D1965
Mr. Jonathan GoChief Technology Officer351.89kN/D1963
Mr. Eric LonnqvistChief Financial OfficerN/DN/DN/D
Ms. Michelle StrongChief Operations OfficerN/DN/DN/D
Ms. Annette L. HerouxVice President of Administration174.9kN/D1957
Mr. Anthony TakazawaDirector of Investor RelationsN/DN/DN/D
Brian TestaChief People OfficerN/DN/DN/D
Mr. Bill KeyesSenior VP of Global Sales OperationsN/DN/DN/D
Mr. Vasu AvadhanulaChief Product OfficerN/DN/DN/D
Mr. Peter GrahamSenior VP of North American SalesN/DN/DN/D
Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

iCAD, Inc. engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company's breast AI suite includes cancer detection, automated density assessment, and breast cancer risk assessment solutions for both 2D and 3D mammography. It offers PowerLook, a back-end architecture platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcifications; and PowerLook Density Assessment provides automated, consistent, and standardized breast density assessments. The company also offers ProFound AI, a deep-learning algorithm designed to detect malignant soft-tissue densities and calcifications in digital breast tomosynthesis; ProFound AI Risk, a clinical decision support tool that provides breast cancer risk estimation based on a screening mammogram; and VeraLook, a solution designed to support detection of colonic polyps in conjunction with Computed Tomography Colonography. In addition, it offers Xoft Axxent electronic brachytherapy systems for the treatment of early-stage breast, non-melanoma skin, and gynecological cancers to university research and community hospitals, cancer care clinics, veterinary facilities, and dermatology offices. The company sells its products through direct sales organizations, as well as through various original equipment manufacturer partners, distributors, technology platform partners, and resellers. It also exports its products in Europe, Taiwan, Canada, China, and internationally. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.

Gestión corporativa

La calificación ISS Governance QuickScore de iCAD, Inc. a partir del 1 de marzo de 2024 es 5. Las puntuaciones principales son Auditoría: 9; Junta: 5; Derechos del accionista: 3; Compensación: 6.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.